These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16250644)

  • 61. Dual NK(1) antagonists--serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives.
    Ryckmans T; Berton O; Grimée R; Kogej T; Lamberty Y; Pasau P; Talaga P; Genicot C
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3195-8. PubMed ID: 12372532
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Selective, centrally acting serotonin 5-HT2 antagonists. 2. Substituted 3-(4-fluorophenyl)-1H-indoles.
    Andersen K; Perregaard J; Arnt J; Nielsen JB; Begtrup M
    J Med Chem; 1992 Dec; 35(26):4823-31. PubMed ID: 1336054
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130.
    Taber MT; Wright RN; Molski TF; Clarke WJ; Brassil PJ; Denhart DJ; Mattson RJ; Lodge NJ
    Pharmacol Biochem Behav; 2005 Mar; 80(3):521-8. PubMed ID: 15740795
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics.
    Chen XW; Sun YY; Fu L; Li JQ
    Eur J Med Chem; 2016 Nov; 123():332-353. PubMed ID: 27487565
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Studies towards the next generation of antidepressants. Part 4: derivatives of 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine with affinity for the serotonin transporter and the 5-HT1A receptor.
    Evrard DA; Zhou P; Yi SY; Zhou D; Smith DL; Sullivan KM; Hornby GA; Schechter LE; Andree TH; Mewshaw RE
    Bioorg Med Chem Lett; 2005 Feb; 15(4):911-4. PubMed ID: 15686885
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
    Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
    J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
    [TBL] [Abstract][Full Text] [Related]  

  • 68. N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.
    Wakenhut F; Allan GA; Fish PV; Fray MJ; Harrison AC; McCoy R; Phillips SC; Ryckmans T; Stobie A; Westbrook D; Westbrook SL; Whitlock GA
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5078-81. PubMed ID: 19647430
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synthesis and preliminary screening of novel N-{2-[4-(substituted)piperazin-1-yl]-2-oxoethyl}acetamides as potential atypical antipsychotic agents.
    Chandra Sekhar KV; Rao VS; Krishna MM
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):871-5. PubMed ID: 18825551
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
    Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
    [TBL] [Abstract][Full Text] [Related]  

  • 71. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents.
    Sekhar KV; Rao VS; Devambatla RKV; Kumar MM
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6054-7. PubMed ID: 18948000
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of a 5-HT7 receptor antagonist DR4004 on the exploratory behavior in a novel environment and on brain monoamine dynamics in mice.
    Takeda H; Tsuji M; Ikoshi H; Yamada T; Masuya J; Iimori M; Matsumiya T
    Eur J Pharmacol; 2005 Jul; 518(1):30-9. PubMed ID: 16002064
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors.
    Asproni B; Pau A; Bitti M; Melosu M; Cerri R; Dazzi L; Seu E; Maciocco E; Sanna E; Busonero F; Talani G; Pusceddu L; Altomare C; Trapani G; Biggio G
    J Med Chem; 2002 Oct; 45(21):4655-68. PubMed ID: 12361392
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synthesis and biological evaluation of 2-(4-fluorophenoxy)-2-phenyl-ethyl piperazines as serotonin-selective reuptake inhibitors with a potentially improved adverse reaction profile.
    Dorsey JM; Miranda MG; Cozzi NV; Pinney KG
    Bioorg Med Chem; 2004 Mar; 12(6):1483-91. PubMed ID: 15018922
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor.
    Barbier AJ; Aluisio L; Lord B; Qu Y; Wilson SJ; Boggs JD; Bonaventure P; Miller K; Fraser I; Dvorak L; Pudiak C; Dugovic C; Shelton J; Mazur C; Letavic MA; Carruthers NI; Lovenberg TW
    Eur J Pharmacol; 2007 Dec; 576(1-3):43-54. PubMed ID: 17765221
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Selective, centrally acting serotonin 5-HT2 antagonists. 1. 2- and 6-substituted 1-phenyl-3-(4-piperidinyl)-1H-indoles.
    Perregaard J; Andersen K; Hyttel J; Sánchez C
    J Med Chem; 1992 Dec; 35(26):4813-22. PubMed ID: 1336053
    [TBL] [Abstract][Full Text] [Related]  

  • 78. trans-1-[(2-Phenylcyclopropyl)methyl]-4-arylpiperazines: mixed dopamine D(2)/D(4) receptor antagonists as potential antipsychotic agents.
    Zhang X; Hodgetts K; Rachwal S; Zhao H; Wasley JW; Craven K; Brodbeck R; Kieltyka A; Hoffman D; Bacolod MD; Girard B; Tran J; Thurkauf A
    J Med Chem; 2000 Oct; 43(21):3923-32. PubMed ID: 11052797
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bivalent dopamine D2 receptor ligands: synthesis and binding properties.
    Kühhorn J; Hübner H; Gmeiner P
    J Med Chem; 2011 Jul; 54(13):4896-903. PubMed ID: 21599022
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
    Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
    Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.